hide message

Welcome to the Resource Centre

We make it our mission to work with advocates in civil society, business and government to address inequalities of power, seek remedy for abuse, and ensure protection of people and planet.

Both companies and impacted communities thank us for the resources and support we provide.

This is only possible because of your support. Please make a donation today.

Thank you,
Phil Bloomer, Executive Director

Donate now hide message

You are being redirected to the story the piece of content is found in so you can read it in context. Please click the following link if you are not automatically redirected within a couple seconds:

Will Pharma, Trade Agreements Shut Down the Pharmacy of the Developing World? [India]

Author: Tido von Schoen-Angerer, Executive Director of Access to Essential Medicines Campaign, Doctors Without Borders, Huffington Post [USA], Published on: 27 April 2010

Pharmaceutical companies are chipping away at India's legal safeguards in the courts...Bayer is attempting to clamp down on and delay the approval process required for generics to be marketed as soon as a patent is licensed, revoked or expires. Novartis, having lost a legal marathon challenging the very constitutionality of the most significant parts of Indian patent law, is now before the Indian Supreme Court to water down the use of these crucial provisions. [also refers to Gilead Sciences]

Read the full post here

Related companies: Bayer Gilead Sciences Novartis